156 related articles for article (PubMed ID: 38092013)
1. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib plus trametinib in patients with BRAF
Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
[TBL] [Abstract][Full Text] [Related]
5. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
7. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
Dutriaux C; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Saiag P
Eur J Cancer; 2022 Nov; 175():254-262. PubMed ID: 36170791
[TBL] [Abstract][Full Text] [Related]
8. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
[TBL] [Abstract][Full Text] [Related]
10. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
Dummer R; Long GV; Robert C; Tawbi HA; Flaherty KT; Ascierto PA; Nathan PD; Rutkowski P; Leonov O; Dutriaux C; Mandalà M; Lorigan P; Ferrucci PF; Grob JJ; Meyer N; Gogas H; Stroyakovskiy D; Arance A; Brase JC; Green S; Haas T; Masood A; Gasal E; Ribas A; Schadendorf D
J Clin Oncol; 2022 May; 40(13):1428-1438. PubMed ID: 35030011
[TBL] [Abstract][Full Text] [Related]
13. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
15. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in patients with
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto PA; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Tumori; 2023 Dec; 109(6):537-545. PubMed ID: 37417313
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
